阿斯特拉加洛西德IV通过抑制WDR5-介导的ENO1 H3K4me3修改来缓解性结肠炎的进展
Su-Xiao Wu1, Zi-Lan Chen1, Xiao-Hong Wang1
1Department of Gastroenterology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, Jiangsu, People's Republic of China.
The Kaohsiung journal of medical sciences
|June 30, 2025
概括
甲酸IV (ASI) 通过抑制WDR5,减少ENO1激活和缓解炎症,有效治疗性结肠炎 (UC). 这种天然化合物为UC患者提供了一个有前途的治疗途径.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一个日益严重的全球健康问题.
- 了解UC背后的分子机制对于开发有效的治疗方法至关重要.
研究的目的:
- 调查阿斯特拉加洛西德IV (ASI) 对DSS诱导的UC的治疗作用.
- 阐明 WDR5 和 ENO1 在 ASI 作用机制中的作用.
主要方法:
- 使用DSS建立了UC的小鼠模型.
- 生物信息学分析 (GSE38713数据库) 确定了关键目标.
- 在体外研究中评估了ASI对NCM460细胞的影响.
- 研究了涉及WDR5,H3K4me3和ENO1的分子机制.
主要成果:
- ASI治疗改善了UC症状,减少了结肠损伤,并减少了炎症标志物.
- 在NCM460细胞中,ASI增加了细胞活力,并恢复了紧结蛋白 (ZO-1,Claudin-3).
- ASI抑制了WDR5,这反过来又减少了ENO1促进体的H3K4me3修饰,从而抑制了ENO1激活和亡.
结论:
- ASI显示了性结肠炎的显著治疗潜力.
- 该机制涉及WDR5/H3K4me3/ENO1通路的抑制.
- ASI为UC治疗提供了一个有前途的天然化合物.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
243
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
243
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.3K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K
Drugs for Treatment of Diarrhea-Predominant IBS
312
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
312
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.2K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.2K
Gastritis-II: Pathophysiology
592
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
592
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204


